Aspirin boost to colon cancer test
10 December 2010
Low-dose aspirin may improve the performance of tests for colorectal cancer, a study suggests.
German researchers looked at the issue because screening for colorectal cancer is often carried out in populations in whom use of low-dose aspirin is common.
Low-dose aspirin increases the risk of gastrointestinal bleeding and so concerns have been raised that it may affect the specificity of tests for colorectal cancer.
Dr Hermann Brenner and colleagues from the German Cancer Research Centre in Heidelberg assessed the performance of immunochemical faecal occult blood tests in around 4,000 people.
They found that the use of low-dose aspirin was associated with a markedly higher sensitivity for detecting advanced colorectal neoplasms, with only a slightly lower specificity.
The researchers said the possibility that test performance may be enhanced by temporary use of low-dose aspirin will need to be followed up in large randomised studies.
- Related MIMS Guidelines and Summaries
- Bosutinib for Previously Treated Chronic Myeloid Leukaemia (TA299)
- Crizotinib for Previously Treated Non-Small-Cell Lung Cancer Associated with an Anaplastic Lymphoma Kinase Fusion Gene (TA296)
- Everolimus in Combination with Exemestane for Treating Advanced HER2-Negative Hormone-Receptor-Positive Breast Cancer after Endocrine Therapy (TA295)
Latest jobs Jobs web feed
- Clinical Research Physician Synexus Ltd Competitive, UK based sites
- Salaried GP DMC Healthcare Competitive Salary, East Dulwich, South London
- Salaried GP The Medical Centre - Kent Competitive, Maidstone, Kent
- Salaried GP Horden Group Practice Salary will be dependant on experience, Horden, County Durham
- Locum GP (Liverpool) Agenda Medical Locums £550 - 650 per day, Liverpool
- Locum GP (Newcastle) Agenda Medical Locums £525 per day, Newcastle